Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis
Oral Janus kinase inhibitors (JAKi) are increasingly used in dermatology, rheumatology, gastroenterology, and hematology. While effective, they can cause adverse effects such as acne, nausea, cytopenia, dyslipidemia, and Herpes zoster. Recent reports have linked JAKi usage to weight changes, particu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | JAAD International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666328724001871 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553809456758784 |
|---|---|
| author | Grace Xiong, BHSc Eric Yu Martin Heung Jaehyeong Yang, BSc Megan Lowe, MPH Mohannad Abu-Hilal, MD |
| author_facet | Grace Xiong, BHSc Eric Yu Martin Heung Jaehyeong Yang, BSc Megan Lowe, MPH Mohannad Abu-Hilal, MD |
| author_sort | Grace Xiong, BHSc |
| collection | DOAJ |
| description | Oral Janus kinase inhibitors (JAKi) are increasingly used in dermatology, rheumatology, gastroenterology, and hematology. While effective, they can cause adverse effects such as acne, nausea, cytopenia, dyslipidemia, and Herpes zoster. Recent reports have linked JAKi usage to weight changes, particularly weight gain, which can significantly impact patients' quality of life. This study aimed to describe the incidence and characteristics of weight changes associated with the use of JAKi. Ovid MEDLINE, Embase, Web of Science, and Clinicaltrials.gov were searched up to April 2024. From 1080 initial articles, 90 studies covering 16,000 patients were selected. Our analysis found a notable incidence of weight gain with JAKi usage. Overall, 5.9% (947/16,000) of patients reported weight again. In randomized control trials, weight gain was observed in 7% (95% CI: 0.04; 0.09) of patients, while weight loss was observed in 1% (95% CI: 0.00; 0.03). Patients with dermatologic indications had lower weight gain rates (4%, 95% CI: 0.01; 0.06) than those with nondermatological indications (7%, 95% CI: 0.04; 0.10). Overall, JAKi therapy is associated with weight changes, particularly weight gain, underscoring the importance of appropriate counseling and weight monitoring. Further long-term studies are needed to better understand the mechanisms and management of JAKi-related weight changes. |
| format | Article |
| id | doaj-art-489933114ccb4f50b0daa7eb832af274 |
| institution | Kabale University |
| issn | 2666-3287 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JAAD International |
| spelling | doaj-art-489933114ccb4f50b0daa7eb832af2742025-01-09T06:14:47ZengElsevierJAAD International2666-32872025-04-011919Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysisGrace Xiong, BHSc0Eric Yu1Martin Heung2Jaehyeong Yang, BSc3Megan Lowe, MPH4Mohannad Abu-Hilal, MD5Michael G. DeGroote School of Medicine, McMaster University, Hamilton, CanadaMichael G. DeGroote School of Medicine, McMaster University, Hamilton, CanadaFaculty of Health Sciences, McMaster University, Hamilton, CanadaMichael G. DeGroote School of Medicine, McMaster University, Hamilton, CanadaQueen's University School of Medicine, Queens University, Kingston, CanadaDivision of Dermatology, McMaster University, Hamilton, Canada; Correspondence to: Mohannad Abu-Hilal, MD, Department of Dermatology, McMaster University, 100 Main St W, Hamilton, Ontario L8P 1H6, Canada.Oral Janus kinase inhibitors (JAKi) are increasingly used in dermatology, rheumatology, gastroenterology, and hematology. While effective, they can cause adverse effects such as acne, nausea, cytopenia, dyslipidemia, and Herpes zoster. Recent reports have linked JAKi usage to weight changes, particularly weight gain, which can significantly impact patients' quality of life. This study aimed to describe the incidence and characteristics of weight changes associated with the use of JAKi. Ovid MEDLINE, Embase, Web of Science, and Clinicaltrials.gov were searched up to April 2024. From 1080 initial articles, 90 studies covering 16,000 patients were selected. Our analysis found a notable incidence of weight gain with JAKi usage. Overall, 5.9% (947/16,000) of patients reported weight again. In randomized control trials, weight gain was observed in 7% (95% CI: 0.04; 0.09) of patients, while weight loss was observed in 1% (95% CI: 0.00; 0.03). Patients with dermatologic indications had lower weight gain rates (4%, 95% CI: 0.01; 0.06) than those with nondermatological indications (7%, 95% CI: 0.04; 0.10). Overall, JAKi therapy is associated with weight changes, particularly weight gain, underscoring the importance of appropriate counseling and weight monitoring. Further long-term studies are needed to better understand the mechanisms and management of JAKi-related weight changes.http://www.sciencedirect.com/science/article/pii/S2666328724001871abrocitinibbaricitinibJanus kinase inhibitorsmedical dermatologyruxolitinibtofacitinib |
| spellingShingle | Grace Xiong, BHSc Eric Yu Martin Heung Jaehyeong Yang, BSc Megan Lowe, MPH Mohannad Abu-Hilal, MD Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis JAAD International abrocitinib baricitinib Janus kinase inhibitors medical dermatology ruxolitinib tofacitinib |
| title | Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis |
| title_full | Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis |
| title_fullStr | Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis |
| title_full_unstemmed | Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis |
| title_short | Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis |
| title_sort | weight gain secondary to the use of oral janus kinase inhibitors a systematic review and meta analysis |
| topic | abrocitinib baricitinib Janus kinase inhibitors medical dermatology ruxolitinib tofacitinib |
| url | http://www.sciencedirect.com/science/article/pii/S2666328724001871 |
| work_keys_str_mv | AT gracexiongbhsc weightgainsecondarytotheuseoforaljanuskinaseinhibitorsasystematicreviewandmetaanalysis AT ericyu weightgainsecondarytotheuseoforaljanuskinaseinhibitorsasystematicreviewandmetaanalysis AT martinheung weightgainsecondarytotheuseoforaljanuskinaseinhibitorsasystematicreviewandmetaanalysis AT jaehyeongyangbsc weightgainsecondarytotheuseoforaljanuskinaseinhibitorsasystematicreviewandmetaanalysis AT meganlowemph weightgainsecondarytotheuseoforaljanuskinaseinhibitorsasystematicreviewandmetaanalysis AT mohannadabuhilalmd weightgainsecondarytotheuseoforaljanuskinaseinhibitorsasystematicreviewandmetaanalysis |